Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MTVABullishIndustry Newsnews

High materiality8/10

MetaVia's DA-1726 Part 3B shows strong liver fat reduction and MetALD potential

Nov 5, 2026, 9:21 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Promising Phase 1B/3-like signals (liver fat, weight, HbA1c) plus a clear Phase 2 path could reduce risk and attract buyers ahead of full data; small sample size and interim nature temper upside.

AI summary

What happened, with direct paths to the underlying reporting

MetaVia reported positive interim Part 3B data for DA-1726, a GLP-1/GCGR dual agonist, showing 68% placebo-adjusted liver fat reduction and 13.5% weight loss after ~16 weeks. All baseline steatosis patients reached MRI-PDFF <5%; no new GI adverse events; full Part 3A/3B data due Q1 2027. A 48-week Phase 2 in MetALD/ALD is planned for late 2027.

DA-1726 Part 3B shows 68% liver fat reduction; 13.5% weight loss.
All baseline steatosis patients reached MRI-PDFF below 5%.
HbA1c declined 0.24 percentage points vs placebo.
No GI adverse events caused discontinuation after Week 9.
Full Part 3A/3B data due Q1 2027; Phase 2 planned H2 2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.